Transplantation of solid organs and hematopoietic stem cells (HSCs) has become a clinical reality over the past 60 years. Progress in surgery, immunology, radiation oncology, and drug development has contributed to this success, with the involvement of numerous other basic science and clinical disciplines. Many critical discoveries were made first in animals before being translated successfully to the clinic. The two fields of clinical transplantation-bone marrow transplantation and solid-organ transplantation-had common origins but have subsequently evolved separately. Each, however, has propelled the other forward in a complementary fashion, benefiting from several advances. One example is the development of more effective immune-based nonspecific immunosuppressive agents. For HSC transplantation (HSCT), the use of newer and more mechanistically focused immunosuppressive agents has resulted in reduced toxicity of conditioning 1 and provided prophylaxis and treatment for graft-versus-host disease (GVHD). In the field of solid-organ transplantation, the goal of replacing vital organs that have been attacked by end-stage disease processes has become clinically attainable because of these new agents. Similarly, the discovery of human leukocyte antigen (HLA) antigens had a beneficial impact on GVHD prevention and on outcomes in solid-organ transplants. 2 The focus of this review is the historical journey toward the induction of immune tolerance, from bench to bedside, and the resulting progress toward reconvergence of HSCT and solid-organ transplantation.
Ever since Billingham et al. reported in 1953 that neonatally induced hematopoietic chimerism is associated with donorspecific tolerance to skin "homografts," 3 the induction of donor-specific tolerance has been aggressively pursued. Their neonatal chimera studies built on the findings by Owen in 1945 that genetically disparate freemartin cattle that shared a common placenta are red blood cell chimeras (Figure 1 ). 4 The fact that this chimerism persisted into adulthood suggested that a tolerant state had been induced. Over the ensuing years, there has been vigorous pursuit of methods of inducing tolerance in recipients of transplanted solid organs, motivated by the fact that conventional immunosuppressive agents are associated with substantial toxicity and require lifelong administration. These toxic effects include hypertension, cardiovascular disease, diabetes and other metabolic complications, osteoporosis, opportunistic infections, renal compromise, and an increase in the rate of malignancy. 5 Transplant recipients are faced with the challenge of managing a schedule of taking 15-25 pills per day. In addition, the cost of maintaining a transplanted organ is substantial, ranging from $15,000 to $25,000 per year. Finally, even if there state art is perfect patient compliance (which is difficult, at best) and the price of the medications is not a hurdle, there is a fixed rate of graft loss due to chronic rejection and the inherent toxicity of the drugs themselves. Therefore, only ~50% of kidney transplants from deceased donors survive beyond 10 years. 6 Although the new generation of immunosuppressive agents has effectively prevented early acute rejection, little progress has been made in improving deteriorating graft survival curves beyond 5 years. In renal transplantation, efforts to minimize immunosuppression in order to avoid the associated toxicities have had limited success, with fewer than 1% of subjects being able to successfully discontinue immunosuppression and maintain stable graft function. 7, 8 Similarly, although a slightly higher percentage of liver transplant recipients can be successfully tapered from immunosuppression, this can currently be achieved only after several years, and only recipients with stable functioning of the organ and no prior rejection episodes on immunosuppressive drug monotherapy are eligible for planned weaning. 9, 10 Moreover, there is no reliable objective biomarker to predict those who will be successfully weaned vs. those in whom rejection will set in during the weaning process. It is currently unknown whether the transplant recipients in whom tapering of immunosuppression fails will experience reduced graft survival; however, even reversible rejection in renal transplants has been correlated with impaired long-term allograft survival. 11, 12 Collectively, these challenges underscore the need for effective and safe approaches to induce donor-specific tolerance in organ transplant recipients. This comprehensive review provides a historic perspective of the 60-year quest to achieve what has commonly been termed "the Holy Grail of transplantation": 13 the induction of donor-specific transplantation tolerance.
Shortly after the reports by Owen and the Medawar group, Main and Prehn showed that radiation chimeras prepared with ablative conditioning were tolerant to donor skin grafts. 14, 15 Lorenz and Uphoff et al. had also observed that ablatively irradiated mice could be rescued from death by infusion of bone marrow cells or splenocytes. 16 Although this rescue was originally hypothesized as being due to humoral factors, Main and Prehn 17 demonstrated that it was actually mediated by a cellular mechanism, and that myeloablatively conditioned adult mice that received allogeneic bone marrow were rescued from ablation and were also tolerant to donor skin grafts. On the basis of these findings, Rapaport and Thomas, in separate studies, validated similar outcomes in dogs, reporting induction of unresponsiveness to canine renal allografts by total body irradiation (TBI) and bone marrow transplantation. 18, 19 The fact that hematopoietic chimerism induces tolerance to organ and tissue transplants has been confirmed in virtually all species tested to date.
A major challenge in translating these tolerance-induction findings to the clinic, with respect to solid-organ transplantation, was to devise methods to avoid the toxicity of ablative conditioning. Although ablative conditioning was acceptable for the use of HSCT in hematologic malignancy, and had evolved in the field of bone marrow transplantation as standard of care, 19 the risk was unacceptable when applied to nonmalignant situations such as solid-organ transplantation. Strategies were therefore pursued to establish chimerism and tolerance with reduced conditioning that could be justified for use in organ-transplant recipients. Monaco et al. reported significant graft prolongation with lymphodepletion using antilymphocyte serum plus donor bone marrow cell infusion. This was demonstrated first in mice and subsequently in a similar conditioning and bone marrow protocol in human kidney transplant recipients. 20, 21 Later, there were attempts by Barber et al. 22 and also extensive studies by Starzl et al. involving infusion of donor bone marrow cells into unconditioned recipients of solidorgan allografts. Although chimerism was not established, a significant reduction in chronic rejection was observed. 23, 24 Similar beneficial effects of pretransplant whole-blood transfusions have also been noted. 25, 26 Ildstad and Sachs extended the model of neonatal tolerance to immunocompetent adult mouse recipients by establishing mixed chimerism. 27 Notably, administration of T cell-depleted syngeneic plus T cell-depleted allogeneic or xenogeneic rat bone marrow cells into ablated mouse recipients resulted in mixed hematopoietic chimerism and robust donor-specific tolerance to skin grafts. The tolerance associated with durable chimerism extended even across species barriers. One critical observation was that animals with 1% donor chimerism showed just as much tolerance as those with 100% donor chimerism, suggesting that complete replacement of the recipient hematopoietic system with that of the donor is not a prerequisite to tolerance induction. This observation continued to reinforce interest in development of nonmyeloablative or reduced-intensity conditioning approaches to establish chimerism. [28] [29] [30] [31] The fact that it is possible to establish chimerism and tolerance with nonmyeloablative conditioning has substantially reduced the risk:benefit ratio pertaining to tolerance-induction efforts in solid-organ transplantation. This was a paradigm shift for bone marrow transplantation, a field that had previously evolved in the context of ablative treatment for hematologic malignancies. 19 The successful clinical application of tolerance-inducing strategies developed in animal models requires that the conditioning process in the recipient be relatively safe and simple to perform and capable of being successfully performed in mismatched donor-recipient combinations and/or outbred recipients. A spectrum of less intense approaches to conditioning has been tested in the context of donor bone marrow cell infusion, including standard immunosuppression with antilymphocyte serum or other lymphodepleting agents to establish microchimerism, 22, 24 using total lymphoid irradiation, [32] [33] [34] [35] and using low-dose TBI to establish macrochimerism. 36, 37 These studies confirmed that HSCs and their progeny have important immunomodulatory features. Although the microchimerism approach did not result in immunosuppression-free donor-specific tolerance in organtransplantation recipients, a significant reduction of chronic rejection was observed. 22, 24, 38, 39 The mechanism of this effect has been attributed to reciprocal clonal exhaustion, 24 although the long-held theory implicating participation of donor or recipient regulatory networks was also increasingly considered. 40, 41 These pioneering studies demonstrated the safety of the HSCbased approach and opened the door for clinical translation. The rest of this review focuses on clinical protocols that are actively state art under way, reviewing outcomes first in unconditioned recipients and subsequently in nonmyeloablatively conditioned recipients.
HSCT AND IMMUNOREGULATION IN RECIPIENTS OF HLA-IDENTICAL TRANSPLANTS: NORTHWESTERN RENAL TRANSPLANT TRIAL
Since an early report by investigators at Duke University in 1972, it had been generally accepted that, in recipients of transplants from HLA-identical donors, complete withdrawal of immunosuppression was not routinely possible. 42 In 2009, however, van de Wetering et al. reported successful withdrawal of antiproliferative immunosuppressive therapy in a group of long-term recipients of HLA-identical transplants who had no history of rejection, leaving them on maintenance low-dose methylprednisolone (5 mg daily). 43 In recent long-term follow-up of these subjects, no acute or chronic rejection has been seen clinically. Protocol biopsies have not been performed (J. van de Wetering, personal communication).
The ongoing study at Northwestern University proposed that immunoregulatory mechanisms might be amplified in recipients of transplants who were HLA-identical and had only minor donor-recipient disparities in major histocompatibility antigen (MHAg), in the context of tolerance-promoting HSCs and the temporary use of immunosuppressive agents to the point of withdrawal. Such regulatory mechanisms had been tested by Medawar in inbred major histocompatibility complex (MHC)-identical MHAg-disparate mice nearly 40 years earlier. Pretreatment of MHC antigen-identical recipients with nonviable donor spleen cell extracts as induction therapy resulted in permanent survival of skin allografts. 44 Tolerance was also achieved in MHCmatched, minor-antigen-disparate mice receiving large (but not small) donor skin allografts-also without viable donor marrow treatment. 45 It was subsequently demonstrated that recipient strain "suppressor cells" in the form of splenocytes would adoptively transfer this graft acceptance to secondary recipients. 41 On the basis of these considerations, a clinical trial of planned slow weaning of immunosuppression in unconditioned HLAidentical living-donor renal transplant recipients was initiated at Northwestern University in 2008. The rationale did not include the need for permanent chimerism, merely the expectation that a prolonged immunoregulatory environment could be provided by donor HSC infusions, without myeloablation but with the use of alemtuzumab, a strongly lymphodepleting anti-CD52 panlymphocytic monoclonal antibody hypothesized to promote a tolerogenic immunoregulatory state. It is hypothesized that the lymphodepletion induced by anti-CD52 promotes an immunoregulatory state with immune reconstitution from homeostatic proliferation of residual lymphocytes. 46 In the study, four donor CD34-selected HSC infusions are performed postoperatively during the first 9 months after renal transplantation. Cell doses range from 0.5 × 10 6 to 4 × 10 6 cells per kilogram of the recipient's body weight. Conventional immunosuppression is tapered after conversion to sirolimus monotherapy. Twenty HLAidentical sibling donor-recipient pair renal transplants have been performed using this approach. The data for the first 10 subjects are summarized in Table 1 . Only transient microchimerism was present, and it had disappeared at the 1-year follow-up ( Table 1) . Immunosuppression is totally withdrawn by 24 months in subjects with stable renal function and normal protocol biopsies. Increased numbers of CD4 + /CD25 high /FoxP3 + regulatory T cells (Tregs) were present in the peripheral blood of these subjects during lymphoid reconstitution, suggesting induction of a long-lasting immunoregulatory state ( Table 1 ). The percentage of Tregs ranged from 0.8 to 4% of total CD4 relative to pretransplant counts. The numbers in the table represent the multiple of change (fold change) from baseline in each subject. These data correlated with donor-specific functional Treg effects that were also seen in an in vitro lymphoproliferation assay. 47 Five of the first 10 recipients followed for longer than 3 years have had immunosuppression successfully withdrawn for between 14 and 24 months. Protocol biopsies 1 year after withdrawal do not show rejection ( Table 1) . Two others had Banff-1A rejection on protocol biopsy 1 year after immunosuppressive withdrawal, without deterioration of renal function. These patients were restarted on standard immunosuppressive therapy. Two others had recurrent disease and immunosuppression was never withdrawn, and an additional recipient could not be weaned from immunosuppression because the protocol biopsy at 24 months after the transplantation was not quiescent. This patient had panel-reactive HLA antibody (PRA) level of 29% preoperatively, suggesting sensitization. At the time of this publication, ~50% of the subjects have been off immunosuppressive agents for >1 year. The subjects in the study range from 2 to 52 months posttransplant. None of the 20 subjects has had deterioration from the optimal renal function that occurred in the early posttransplant period. This is in contrast to a much lower success rate in HLA-mismatched subjects weaned earlier after transplant. 10 To our knowledge, and from an examination of the published literature, the studies described herein are the only ones of this nature attempted to date.
HSCT IN CONDITIONED, HLA-IDENTICAL RELATED KIDNEY RECIPIENTS: THE STANFORD STUDY
In 1977, Slavin et al. reported that donor-specific transplantation tolerance could be achieved for skin allografts using fractionated total lymphoid irradiation (TLI) followed by infusion of donor bone marrow cells in adult mice. 31, 32, 34 This study was conceived as a result of a clinical protocol using TLI at that center, a protocol developed for radiotherapy of Hodgkin's disease. 48 The Slavin/Strober approach established durable chimerism in mismatched mice and was described by the authors as being clinically relevant because the conditioning was seen to be relatively safe in humans. It was subsequently reported that TLI could be used successfully in larger outbred species to establish chimerism and tolerance. 49, 50 The findings from subsequent extensive preclinical investigations were successfully translated to the clinic starting in 2005. A total of 16 HLA-identical, living-donor, sibling kidney transplant recipients were conditioned with fractionated TLI (800 or 1,200 cGy total); this was followed by infusion of CD34 + selected donor bone marrow cells supplemented with 1 × 10 6 CD3 + T cells/kg. 35 Conditioning consisted of rabbit antithymocyte globulin, methylprednisolone, the fractionated TLI, and conventional immunosuppression (Figure 2b) .
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The recipients were initially maintained on cyclosporine and mycophenolate mofetil per standard of care. In the early subjects, the cyclosporine was tapered off starting at 3 months and discontinued at 6 months if stable chimerism was attained with no GVHD. 33 Later, weaning of immunosuppression was performed in situations in which there was no clinical evidence of rejection and a protocol biopsy was normal, irrespective of whether chimerism had persisted. 35 Of 16 subjects, 3 experienced rejection during the tapering of immunosuppression and were restarted on conventional immunosuppression. One subject experienced recurrent disease. The others were completely weaned from immunosuppression and have maintained stable renal function. Of note, protocol biopsies were not performed. The hospital stay was not prolonged by the conditioning. This study demonstrated the safety and feasibility of the TLI-based conditioning in renal transplant recipients. An added benefit is that, because the conditioning process and infusion of the HSCT product were performed after kidney graft placement, they could theoretically be applied even in recipients of deceased-donor organs, who comprise the substantial majority of transplant recipients.
One major limitation to this approach is the requirement for HLA-related and matched donors, given that almost all deceased-donor organ transplants are unrelated and unmatched. In fact, a similar TLI-ALG conditioning regimen was tested by the group before the HLA-identical study in HLA-mismatched recipients from 2000-2004. 32 In these recipients of mismatched transplants, three of the four developed whole-blood macrochimerism, with the highest level being 16% donor. However, chimerism was lost in all the subjects within 3 months. Hence, one of the more stringent requirements for successful translation of stem cell-based therapies to the clinic-the ability to successfully perform the procedure in recipients of mismatched transplants-has yet to be met.
THE MASSACHUSETTS GENERAL HOSPITAL KIDNEY/HSCT STUDY IN CONDITIONED, RELATED, HAPLOIDENTICAL KIDNEY/HSCT RECIPIENTS
Extensive mechanism-based preclinical studies in mice and nonhuman primates resulted in the Massachusetts General Hospital (MGH) clinical combined kidney/HSCT tolerance protocol. In studies using mice, it was observed that low-dose irradiation plus in vivo administration of T-cell lymphodepleting agents almost completely eliminated peripheral but not thymic T cells. 28 The addition of 700 cGy of thymic irradiation to the conditioning resulted in durable chimerism and tolerance induction. 28 Translation of this approach to a nonhuman primate model did not achieve durable chimerism but resulted in operational tolerance. 51 It was hypothesized that, although chimerism was required to induce tolerance, it was not required state art for its maintenance, and that immune regulation would be able to maintain the tolerant state after the loss of chimerism. Donor antigen from the kidney allograft was believed to directly contribute to the regulatory mechanism. 51 These preclinical studies were subsequently formulated into a clinical trial. Beginning in 2002, a total of 10 subjects were transplanted with unmodified granulocyte colony-stimulating factor-mobilized HSCT from related haploidentical donors. [52] [53] [54] All subjects exhibited low levels of donor chimerism in the peripheral blood for up to 21 days, as assessed by flow cytometric analysis. One subject (the third to be enrolled) developed irreversible humoral rejection, resulting in loss of the renal allograft. 51, 52 As a result, anti-CD20 monoclonal antibody treatment was added to the recipient conditioning regimen to target B cells and humoral immunity. A second subject developed acute cellular rejection 7 weeks after immunosuppression had been discontinued and coincident with a viral infection, with subsequent graft loss. 13 A third subject developed the expected "engraftment syndrome" observed in 9 of the 10 recipients, and renal function did not normalize. 53 After discontinuation of cyclosporine consequent to the presumptive diagnosis of calcineurin inhibitor-induced microangiopathy, the graft was lost. Therefore, 3 of the 10 subjects experienced graft loss. 53 A fourth subject has developed evidence of chronic rejection, manifesting as C4d deposition in the biopsy sample and also as histologic abnormalities. 51 Anti-class II antibodies have also However, several unexplained side effects were experienced by subjects in this study. Transient "engraftment syndrome" occurred in 9 of the 10 subjects, manifesting as acute renal dysfunction, edema, capillary leak syndrome, and fluid retention starting on postoperative day 10-12. An accompanying significant rise in creatinine, combined with the histologic abnormalities observed in some of the subjects, leads to the question of whether these findings suggest atypical rejection. The subjects who developed engraftment syndrome were presumptively treated for rejection. Of note, all the subjects exhibited donorspecific tolerance in mixed lymphocyte reaction (MLR) assays, despite the varying outcomes. 51, 52, 55 
DONOR HSCT PLUS LOW-INTENSITY CONDITIONING WITH 200 CGY/FLUDARABINE/CYCLOPHOSPHAMIDE IN MISMATCHED KIDNEY RECIPIENTS
The clinical protocol for this study was predicated on two observations made initially in studies in small animals: the nonmyeloablative conditioning approach and the engineering of the donor HSC product to reduce the risk of GVHD. Using a dose titration of TBI in a mouse model for HSCT, it was determined that if immune-based immunosuppression was added to the conditioning, the TBI dose could be significantly reduced. 29, 30 The addition of cyclophosphamide to the regimen 2-3 days after transplantation allowed an additional reduction in the minimum TBI dose required to establish durable chimerism. 30 The cyclophosphamide mechanistically targets alloreactive donor and recipient cells and spares the HSCs. This was validated successfully in a dog model 56 and applied to human subjects in pioneering work by Fuchs et al. 57 In the latter study, subjects with hematologic malignancies and comorbidities that precluded ablative conditioning were enrolled and managed as outpatients. The subjects were conditioned with fludarabine (30 mg/m 2 /day on days −6 to −2), cyclophosphamide (50 mg/kg/dose on days −6, −5, +3, and/or +4), and 200 cGy TBI on day −1, followed by transplantation of unmanipulated granulocyte colony-stimulating factormobilized HSCT on day 0. The safety of this approach has now been confirmed in a large number of subjects, and significant reductions in transplant-related morbidity and mortality have occurred. These landmark studies have significantly impacted the field of HSCT. Graft failure occurred in only 13% of the subjects, and the cumulative incidence of grade II-IV acute GVHD was substantially reduced to 43% in haploidentical recipients, with 10% being grade III-IV GVHD and 10% chronic GVHD. 58, 59 Although this level of GVHD was an acceptable risk-to-benefit ratio in the setting of hematologic malignancy, it would be unacceptable in the context of kidney transplantation. As discussed below, the current use of this refined low-intensity conditioning regimen together with an engineered HSCT product has all but eliminated GVHD in recipients of mismatched kidney/HSCT transplants.
ENGINEERING THE HSC GRAFT: THE FACILITATING CELL
The first description of the facilitating cell (FC) was made in mice almost 20 years ago. Experiments using rare-events cell sorting identified a novel CD8 + /TCR − bone marrow-derived cell that was necessary and sufficient to enable engraftment of purified HSCs in ablated allogeneic recipients. 60 This work, which had once been considered controversial, was reproduced 61 Subsequently, much has been done to define critical FC subpopulations and their mechanisms of action. The CD8 + /TCR − FC population is heterogeneous. 60, 61 Plasmacytoid precursor dendritic cells (p-preDCs) comprise a major component of FCs. 62 Removal of p-pre-DC FCs cripples FC function, but p-preDCs and p-preDC FCs do not totally replace FCs in their facilitating function. Therefore, p-pre DC FCs are critical but not sufficient for FC function. FCs produce physiologically relevant levels of tumor necrosis factor-α when co-cultured with HSCs, 63 and they also induce antigen-specific Tregs in vivo 64 and in vitro. 65 Removal of p-preDC FCs abrogates the induction of Treg cells in vivo. 64 FCs express a unique cell surface receptor complexed with CD3ε. 66 After discovery of FCs, and before embarking on clinical trials, we confirmed that a similar CD8 + /TCR − FC population exists in humans. 67 The existence of FCs in humans has also been confirmed independently. 68 An approach to bioengineering human marrow to remove GVHD-inducing immune cells and to preserve FCs, HSCs, and progenitors was developed, validated, and submitted to the FDA in 1996, followed by the first clinical trial to utilize FC manufacturing technology in subjects with hematologic malignancy for whom a suitably matched donor was not available. 69 Specifically, in an approach involving ferromagnetism, monoclonal antibodies were used to remove mature GVHDinducing immune cells of the donor while retaining FCs, HSCs, and progenitors. In 54 ablatively conditioned, related as well as unrelated, mismatched donor transplants, we confirmed that we could establish engraftment and avoid the occurrence of GVHD. This success opened the door to clinical trials to induce tolerance in organ-transplant recipients.
In 2009, a phase II clinical trial combining living-donor kidney transplantation and HSCT was initiated in a collaboration between the Institute for Cellular Therapeutics (ICT) at the University of Louisville and Northwestern University. 67 To date, 15 HLA-mismatched, related as well as unrelated, subjects have been enrolled and have received transplants. 70 Conditioning consisted of three doses of fludarabine (30 mg/ kg/dose) on days −4, −3, and −2; two doses of cyclophosphamide (50 mg/kg/dose) on days −3 and +3; and 200 cGy TBI on day −1 relative to the renal transplant (day 0) (Figure 3) .
Hemodialysis was performed 6-8 h after the administration of fludarabine and cyclophosphamide to avoid toxicity from these agents before the transplantation process. Tacrolimus (target trough concentrations 8-12 ng/ml) and mycophenolate mofetil (1 g orally twice daily in recipients of body weight <80 kg and 1.25 g twice daily in recipients of body weight ≥80 kg) were started on day −3 and continued as maintenance immunosuppression after the transplant procedure. Kidney transplantation was performed without antibody induction or oral corticosteroid therapy. The bioengineered, FDA-regulated, heavily manipulated HSC product, enriched for FCs, was infused intravenously on the day after living-donor kidney transplantation. The subjects were discharged on postoperative day 2 and thereafter managed as outpatients. All but one patient demonstrated peripheral blood macrochimerism after the transplantation. Engraftment failure occurred in one highly sensitized (PRA >54%) transplant recipient. Chimerism was lost in three patients at 2, 3, and 6 months after transplantation. Two of those subjects had received a reduced cell dose and/or incomplete conditioning; the other had a PRA >20%. In all 11 of the remaining subjects, who had received full conditioning and the target cell dose, high levels of chimerism were observed. All subjects demonstrated donor-specific hyporesponsiveness and were weaned from full-dose immunosuppression. Complete withdrawal of immunosuppression was successfully accomplished at 1 year after transplantation in all the subjects with durable chimerism. There has been no occurrence of GVHD or engraftment syndrome. One chimeric subject developed sepsis following an atypical viral infection at month 3 after transplantation, leading to renal artery thrombosis and loss of the graft; this subject subsequently underwent a successful retransplantation procedure.
Initially, the study's primary end point for tapering and discontinuing immunosuppression was the development of donorspecific hyporesponsiveness. However, after two subjects with only transient chimerism demonstrated subclinical rejection on protocol biopsy in spite of donor-specific hyporesponsiveness in MLR and cell-mediated lympholysis assays, we modified the primary end point to attainment of durable T-cell and whole-blood chimerism. 70 These data suggest that low-intensity conditioning plus FC-enriched HSCs can safely achieve durable chimerism and successful withdrawal of immunosuppression in recipients of mismatched allografts, without the occurrence of GVHD or engraftment syndrome. Nonspecific sensitization appears to represent an obstacle to successful induction of chimerism and tolerance. The presence of sustained T-cell chimerism serves as a more robust tolerance biomarker than donor-specific hyporeactivity in vitro.
BIOMARKERS OF TOLERANCE: IS CHIMERISM THE NEW STANDARD?
The MLR proliferative and cell-mediated lympholysis assays have been considered the gold-standard test for tolerance. It is interesting that some of the transiently chimeric subjects treated in the MGH study, the Stanford study, and the Northwestern/ICT study exhibited donor-specific hypoactivity In the Northwestern University/ICT trial, two subjects who had transient chimerism and donor-specific hyporesponsiveness in vitro for up to 18 months demonstrated subclinical Banff-1A rejection on protocol biopsy, which resolved with antirejection therapy. Similarly, although all the MGH subjects were reported to exhibit donor-specific hyporesponsiveness, three developed rejection and a fourth has C4d deposition on biopsy. Therefore, it appears that durable chimerism is the most robust biomarker for tolerance. The metric of T-cell chimerism in HSCT has long been considered a predictor of durable engraftment. 71 
THE FUTURE: DELAYED TOLERANCE
In most countries, the majority of organs transplanted are from deceased donors. One final challenge to be addressed to make tolerance widely available is that it must be ensured that the HSCT product either is infused within 48 h of being harvested or is appropriately cryopreserved. Because the conditioning process takes ~5 days, an approach for delayed tolerance would be beneficial. Moreover, recipients of solid-organ transplants (hearts, lungs, and livers) are quite ill at the time of the procedure; it would be beneficial for the conditioning and HSCT to be performed after a suitable delay to allow the patient to recover from the transplantation procedure. Such an approach would also benefit individuals who have already received a transplant from a living donor who is willing and able to donate HSCs for therapy. The fact that in the Northwestern University/ICT and Stanford studies the HSCT product had been cryopreserved but yet successfully engrafted brings this possibility one step closer to reality. A clinical protocol to address the living-donor scenario has been approved at Northwestern University (FDA IND 14900; ClinicalTrials.gov) and is ready to begin enrollment. The HSCT sources from deceased donors would be the vertebral columns, as validated in several of the clinical protocols reviewed in this article.
IMPLICATIONS FOR OTHER DISORDERS
HSCs produce the entire immune system of the donor. Durable chimerism can therefore be used to provide a sustained source of normal red blood cells, platelets, white blood cells, and enzyme produced by HSC-derived cells, even if the latter are defective. One additional potential transformational application is the use of HSCT to reverse autoimmunity in type 1 diabetes, 72 systemic lupus erythematosus, rheumatoid arthritis, 73 scleroderma, 74 and other autoimmune disorders (Figure 4) . 75 Collectively, autoimmune disorders affect ~4% of the population worldwide. Currently, only disease-modifying therapies are available. A simple and safe method of performing HSCT in mismatched and unmatched recipients may provide hope for persons with numerous disorders (such as metachromatic leukodystrophy and numerous other inherited metabolic disorders) for which there are no alternative therapies. In summary, the field has reached a point where donor-specific tolerance is clearly within reach. This has been the result of contributions made by numerous investigators in work spanning more than 60 years. The most important beneficiaries will be the patients who may no longer need to experience the severe consequences of immunosuppressive therapy. We are grateful to the subjects who, over the decades, have bravely enrolled in clinical trials that have brought us to the dawn of a new era in transplantation.
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